Neumora Therapeutics (NMRA) Cash from Investing Activities (2022 - 2026)

Neumora Therapeutics' Cash from Investing Activities history runs 5 years deep, the most recent figure standing at $71000.0 for Q1 2026.

• On a quarterly basis, Cash from Investing Activities fell 99.84% year-over-year to $71000.0 in Q1 2026; TTM through Mar 2026 was $124.4 million, a 0.67% increase from a year earlier, with the FY2025 full-year figure at $168.5 million, up 338.84% from the prior year.
• Cash from Investing Activities eased to $71000.0 in Q1 2026 per NMRA's latest filing, from $42.6 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $157.0 million in Q3 2024 and bottomed at -$150.0 million in Q1 2024.
• The 5-year median for Cash from Investing Activities is $22.5 million (2023), against an average of $11.0 million.
• Biggest YoY gain for Cash from Investing Activities was 559.2% in 2024; the steepest drop was 5424.85% in 2024.
• Year by year, Cash from Investing Activities stood at -$8.0 million in 2022, then surged by 270.32% to $13.7 million in 2023, then sank by 822.37% to -$98.8 million in 2024, then surged by 143.16% to $42.6 million in 2025, then slumped by 99.83% to $71000.0 in 2026.
• Per Business Quant, the three latest NMRA Cash from Investing Activities figures stand at $71000.0 (Q1 2026), $42.6 million (Q4 2025), and $51.3 million (Q3 2025).